Status:
COMPLETED
Acquiring Convalescent Specimens for COVID-19 Antibodies
Lead Sponsor:
Columbia University
Conditions:
COVID-19
Coronavirus Infection
Eligibility:
All Genders
18-65 years
Brief Summary
Blood samples from participants who have recovered from COVID-19 infection will be obtained and studied. The goal of the research is to identify antibodies that have been generated by the patient to f...
Detailed Description
Coronavirus disease (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 1,273,712 infections and over 69,458 deaths worldwide. Col...
Eligibility Criteria
Inclusion
- Age 18 to 65 (inclusive)
- Confirmed COVID-19 infection by a FDA-approved molecular based assay (including those under emergency use authorization) of respiratory or blood specimens;
- If symptomatic with COVID-19, must have evidence of improvement of symptoms and a duration of at least 4 weeks from the onset of symptoms to day of enrollment;
- If asymptomatic, must have a duration of at least 4 weeks from first positive molecular based COVID-19 assay to day of enrollment
Exclusion
- \<18 years or \>65 years old
- No confirmed diagnosis of COVID-19
Key Trial Info
Start Date :
March 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 12 2021
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04342195
Start Date
March 25 2020
End Date
March 12 2021
Last Update
July 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Irving Medical Center/NYP
New York, New York, United States, 10032